UPCC 13324: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma.
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
This is a phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab for the first-line (1L) treatment of recurrent or metastatic, programmed cell death protein ligand 1+ (PD-L1+) head and neck squamous cell carcinoma (HNSCC) in patients with combined positive score (CPS) 1.
We would like to rely on Advarra as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
09 Oct 2024.
Study ID: 856716
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
